Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ivy Rx vs Medsol RX

Ivy Rx
Graded #178

Higher grade

vs+5.799999999999997
Medsol RX
Graded #306

Lower grade

The verdict

Ivy Rx takes it — 66.8/100 to 61/100.

Ivy Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth provider offering tiered compounded semaglutide and tirzepatide programs.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueIvy Rx +17
62
45
Dose & formulationEven
64
64
Clinical oversightIvy Rx +3
82
79
Labs & monitoringEven
53
53
FulfillmentMedsol RX +2
81
83
Contract termsIvy Rx +14
55
41
Ivy Rx · left barMedsol RX · right bar

The numbers

MetricIvy RxMedsol RX
WeighScore66.8/10061/100
GradeCC
Scorecard rank#178#306
Semaglutide$175/mo (starting dose, compounded)$209/mo (compounded)
Tirzepatide$275/mo (starting dose, compounded)$250/mo (compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Ivy Rx

Graded #178 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
Medsol RX

Graded #306 · C

Strengths

  • Compounded semaglutide from $209/mo (12-mo plan) and tirzepatide from ~$250/mo; HSA/FSA eligible with Klarna financing
  • Every plan bundles the medication, a dedicated care coach, custom treatment plan, medical oversight, and free shipping
  • Board-certified clinicians via OpenLoop; same-day approvals; ships nationwide
  • Month-to-month option ($199 first month) with no long-term commitment, plus microdosing and wellness add-ons

Where it loses points

  • Doesn't name its compounding pharmacy (generic 'certified U.S. pharmacies')
  • No legal entity name published on the site
  • Tirzepatide pricing is given as a range ($250-$1,400/mo), not a fixed rate
  • Compounded GLP-1s are not FDA-approved (the site discloses this)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard